Cancer screening is an integral component of preventive medicine, aiming to detect malignancies at an early, more treatable stage before symptoms manifest. These screenings involve systematic examinations or tests to identify cancer or precancerous conditions in individuals who may not yet show any signs of the disease. Common cancer screening methods include mammography for breast cancer, Pap smears for cervical cancer, colonoscopies for colorectal cancer, and prostate-specific antigen (PSA) tests for prostate cancer. The goal is to catch abnormalities before they progress, allowing for timely intervention and increased chances of successful treatment. While screening recommendations may vary based on age, gender, and risk factors, the overarching objective is to facilitate early detection, which is a cornerstone of preventive medicine. Regular screenings, coupled with a comprehensive understanding of personal risk factors, empower individuals and healthcare providers to collaborate effectively in managing and mitigating the impact of cancer, aligning with the broader goal of promoting health and well-being through preventive measures.
Speaker lineup for this track will be announced soon.
Browse all speakers →Breast cancer remains the most common malignancy among women globally, yet awareness and early screening practices remain low in low- and middle-income countries like India. To assess and compare…
Objectives: Colorectal cancer incidence and mortality rates are increasing in low- and middle-income countries (LMIC) including North and Central Asian Countries (NCAC). Colorectal cancer (CRC) is…
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Oral and poster slots for original Cancer screening work, reviewed by the scientific committee.
Meet public health researchers, educators, and policy leaders from around the world across three days.
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Plenary lectures from leading voices shaping Cancer screening research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Cancer screening track is a dedicated stream within IPHC 2027 covering the latest research, innovation, and best practice in Cancer screening. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Public health researchers, practitioners, epidemiologists, educators, doctoral students, and policy leaders with an interest in Cancer screening are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. IPHC 2027 is a hybrid conference — attend the Cancer screening track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
